Takeda, Cognition Kit collaborate on wearable app for depression

Jessica Kim Cohen - Print  | 

Takeda Pharmaceuticals and Cognition Kit, a wearable platform that monitors brain health, have partnered for a pilot study on major depressive disorder.

The study, which will involve 30 participants, will investigate the use of a specially designed app on an Apple Watch wearable. The app will collect real-time mental health data in an effort to assess cognitive function in the participants, all of whom have a clinical diagnosis of mild to moderate depression and have been prescribed an antidepressant.

The goal of the study is to understand how measures of mood and cognition on wearable technology compare to more traditional neuropsychological testing and patient-reported assessments.

More articles on health IT:
The 8 most common healthcare apps clinicians want to create
IBM Watson Health medical imaging collaborative adds 8 members
Philips rolls out Jovia Coach app for Type 2 diabetes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.